Immunocompetent murine models for the study of glioblastoma immunotherapy

Taemin Oh*, Shayan Fakurnejad, Eli T. Sayegh, Aaron J. Clark, Michael E. Ivan, Matthew Z. Sun, Michael Safaee, Orin Bloch, Charles D. James, Andrew T. Parsa

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

159 Scopus citations


Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part due to tumor-induced immunosuppressive mechanisms that promote immune escape and immuno-resistance. Immunotherapeutic strategies aimed at bolstering the immune response while neutralizing immunosuppression will play a critical role in improving treatment outcomes for glioblastoma patients. In vivo murine models of glioma provide an invaluable resource to achieving that end, and their use is an essential part of the preclinical workup for novel therapeutics that need to be tested in animal models prior to testing experimental therapies in patients. In this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A (C57BL/6), SMA-560 (VM/Dk), and 4C8 (B6D2F1), each of which offer a suitable platform for testing novel immunotherapeutic approaches.

Original languageEnglish (US)
Article number107
JournalJournal of Translational Medicine
Issue number1
StatePublished - Apr 29 2014


  • Animal models
  • Astrocytoma
  • Glioblastoma
  • Glioma
  • Immune response
  • Immunosuppression
  • Immunotherapy
  • Murine
  • Preclinical

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Immunocompetent murine models for the study of glioblastoma immunotherapy'. Together they form a unique fingerprint.

Cite this